IL-28A/IFN-lambda 2 Antibody [Unconjugated]

IL-28A/IFN-lambda 2 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) treated with calcium ionomycin and PMA using Goat Anti-Human IL-28A/IFN-lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Recombinant Human IL‑28A/IFN‑ lambda 2 (Catalog # 1587‑IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant HumanIL‑28A/IFN‑ lambda 2 (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL‑28A/IFN‑ lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587). The ND50 is typically 0.3-1.5 µg/mL.

Recombinant Human IL‑28A/IFN‑ lambda 2 protein was serially diluted 2-fold and captured by Mouse Anti-Human IL‑28A/IFN‑ lambda 2 Monoclonal Antibody (Catalog # MAB15872) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human IL‑28A/IFN‑ lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998) followed by Substrate Solution (Catalog # DY999) and stopping the enzymatic reaction with Stop Solution (Catalog # DY994).

• Reactivity: Hu
• Applications: WB, ELISA, B/N, ICC/IF
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

IL-28A/IFN-lambda 2 Antibody [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human IL-28A/IFN-lambda 2
  Val26-Val200
  Accession # Q8IZJ0
• Specificity: Detects human IL‑28A/IFN‑ lambda 2 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 60% cross-reactivity with human IL‑28B/IFN‑ lambda 3 is observed. In direct ELISAs, approximately 30% cross-reactivity with recombinant human IL-29 and less than 5% cross‑reactivity with recombinant mouse IL‑28 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: IFNL2
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • ELISA
  • Immunocytochemistry 5-15 ug/mL
  • Neutralization 0.3-1.5 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-28A/IFN-lambda 2 Antibody [Unconjugated]

• interleukin-28A
• IFN-lambda 2
• IL28A
• IL-28A
• interferon, lambda 2

Background

IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% aa sequence identity) and type I IFN family (15-19% aa sequence identity) (1-3). The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons. The exon organization of these genes is also found in the IL-10 family genes but is distinct from the type I IFNs, which are encoded within a single exon, The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including anti-viral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor  beta (IL-10 R beta ) and a novel IL-28 receptor alpha (IL-28 R alpha , also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory regions of the target genes. Human IL-28A cDNA encodes a 200 amino acid (aa) residue precursor protein with a putative 25 aa signal peptide. It shares 94% and 67% aa sequence identity with human IL-28B and human IL-29, respectively.

1. Vilcek, J. (2003) Nature Immunol. 4:8.
2. Sheppard, P. et al. (2003) Nature Immunol. 4:63.
3. Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-28A/IFN-lambda 2 Antibody (AF1587)(4)

Publications using AF1587

• G Gallo, P Kotlik, P Roingeard, M Monot, G Chevreux, RG Ulrich, N Tordo, M Ermonval Diverse susceptibilities and responses of human and rodent cells to orthohantavirus infection reveal different levels of cellular restriction PloS Neglected Tropical Diseases, 2022-10-12;16(10):e0010844. 2022-10-12 [PMID: 36223391] (Neutralization, Mouse)
• Interleukin-28A triggers wound healing migration of bladder cancer cells via NF-kappaB-mediated MMP-9 expression inducing the MAPK pathway. Cell. Signal., 2012-04-25;24(9):1734-42. 2012-04-25 [PMID: 22560878] (Western Blot, Human)
• Li Q, Kawamura K, Okamoto S, Fujie H, Numasaki M, Namba M, Nagata M, Shimada H, Kobayashi H, Tagawa M Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-lambda genes produced anti-tumour effects. Br. J. Cancer, 2011-09-27;105(9):1302-12. 2011-09-27 [PMID: 21952623] (Western Blot, Human)
• Joseph Prescott, Pamela Hall, Mariana Acuna-Retamar, Chunyan Ye, Marc G. Wathelet, Hideki Ebihara et al. New World hantaviruses activate IFNlambda production in type I IFN-deficient vero E6 cells PLoS ONE 2010-06-17 [PMID: 20567522]

Bioinformatics

• Gene Symbol: IFNL2
• Uniprot:
  • Q8IZJ0()